View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
TUESDAY, June 1 (HealthDay News) -- The U.S. Food and Drug Administration has notified health care professionals not to use intravenous medications including metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences, as the products may be contaminated.
The FDA alerted health care professionals because of reports of white floating matter in the intravenous bags of metronidazole and ondansetron. Intravenous products that could potentially be affected include those sold under the Claris, Sagent Pharmaceuticals, Pfizer, and West-Ward Pharmaceuticals labels.
The Cladosporium mold was identified after microbiological analysis was performed due to a Claris customer receiving a complaint of white matter in a bag of metronidazole. In susceptible patients, this type of mold can cause infections. In addition, another bag of ondansetron is being investigated due to a complaint of white matter in an intravenous bag. The FDA recommends that these products not be used and immediately removed from pharmacy inventories.
"Claris is initiating a recall of all lots of these two products, as well as all lots of ciprofloxacin. These products were all manufactured on the same manufacturing line. FDA is investigating the situation and will notify the public when new information becomes available," according to a recent FDA public health alert.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top